Skip to main content

Table 3 Outcomes of patients not undergoing surgery for primary malignant melanoma of esophagus

From: Clinical characteristics and treatment outcomes of primary malignant melanoma of esophagus: a single center experience

No

Age

Sex

Tumor morphology

Metastases

BRAF

PD-L1 (TPS)

1st treatment

Time to progression

2nd treatment

Time to progression

3rd treatment

Time to progression

Overall survival (months)

Outcome

1

64

M

Diffusely infiltrative

LN, adrenal gland

N/A

0%

Nivolumab

24 months

DPT

2 months

Trastuzumab + Deruxtecan (Clinical trial)

Alive by 2021.06.30

34

Alive

2

82

M

Mass-forming

None

N/A

N/A

Pembrolizumab

2 months

DPT

8 months

Supportive care

 

18

Dead

3

63

M

Mass-forming

Lung, liver, LN, adrenal gland, thyroid

N/A

N/A

DBPT

2 months

IFN α

2 months

Supportive care

 

10

Dead

4

83

M

Mass-forming

None

N/A

N/A

Supportive care

     

6

Dead

5

60

M

Mass-forming

Bone, LN

Not detected

N/A

RT

1 week

DPT

2 months

Ipilimumab

1 month

5

Dead

  1. PD-L1 programmed death-ligand 1, TPS tumor proportion score, M male, LN lymph node, DPT Dacarbazine + Cisplatin ± Tamoxifen, DBPT Dacarbazine + Carmustine + Cisplatin ± Tamoxifen, RT radiotherapy, IFN-α interferon alpha, N/A not available